Terrie Curran Biography and Net Worth

Terrie Curran has served as a member of our board of directors since November 2020. Ms Curran is CEO and president at Phathom Pharmaceuticals (Nasdaq: PHAT), a late-clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal diseases. Prior to this, she was the president, global inflammation and immunology (I&I) franchise and member of the executive committee at Celgene. She joined Celgene in 2013 as the US commercial head of the I&I franchise and built the capabilities and recruited the teams that executed the successful launch of Otezla^® for moderate-to-severe plaque psoriasis. Prior to joining Celgene, she served as senior vice president and general manager, global women’s health at Merck & Co. Ms Curran holds graduate and bachelor’s degrees from the University of Technology Sydney.

What is Terrie Curran's net worth?: The estimated net worth of Terrie Curran is at least $5.27 million as of January 21st, 2025. Ms. Curran owns 360,465 shares of Arcutis Biotherapeutics stock worth more than $5,269,998 as of March 15th. This net worth evaluation does not reflect any other assets that Ms. Curran may own. Learn More about Terrie Curran's net worth.
How do I contact Terrie Curran?: The corporate mailing address for Ms. Curran and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at ir@arcutis.com. Learn More on Terrie Curran's contact information.
Has Terrie Curran been buying or selling shares of Arcutis Biotherapeutics?: Terrie Curran has not been actively trading shares of Arcutis Biotherapeutics during the past quarter. Most recently, Terrie Curran sold 8,687 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $10.85, for a transaction totalling $94,253.95. Following the completion of the sale, the director now directly owns 10,139 shares of the company's stock, valued at $110,008.15. Learn More on Terrie Curran's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 1 times. They purchased a total of 1,093 shares worth more than $7,771.23. During the last year, insiders at the sold shares 25 times. They sold a total of 204,162 shares worth more than $2,214,551.74. The most recent insider tranaction occured on March, 3rd when insider Patrick Burnett sold 2,819 shares worth more than $36,731.57. Insiders at Arcutis Biotherapeutics own 9.5% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 3/3/2025.

Terrie Curran Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/11/2024	Sell	8,687	$10.85	$94,253.95	10,139

Terrie Curran Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $14.62

$14.51

$15.38

50 Day Range

MA: $13.52

$11.40

$15.76

2 Week Range

Now: $14.62

$6.99

$16.20

Volume

1,689,885 shs

Average Volume

2,433,515 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48